99mTc-Maraciclatide Radiopharmaceutical for Endometriosis Imaging
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for diagnosing endometriosis are invasive, unreliable, and often require surgical intervention, with existing non-invasive techniques having inadequate diagnostic accuracy and limited ability to detect superficial endometriotic lesions.
Innovation Solution
A non-invasive radiopharmaceutical imaging method using 99mTc-maraciclatide, which is administered to the subject and imaged using a gamma camera or detector, allowing for the visualization of endometriosis sites in the abdomen, pelvis, and thorax without the need for surgical intervention.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If invasive laparoscopic surgery is used for diagnosis, then diagnostic accuracy is improved, but patient trauma and complexity of procedure worsen
Solution Approach 1:
The patent replaces the mechanical surgical intervention (laparoscopy) with a non-invasive nuclear medicine imaging technique. The radiopharmaceutical 99mTc-maraciclatide is administered systemically and accumulates at endometriosis sites, allowing diagnosis through gamma camera imaging without mechanical surgical intervention, thus eliminating patient trauma while maintaining diagnostic accuracy.
Solution Approach 2:
The patent introduces an intermediary substance (99mTc-maraciclatide radiopharmaceutical) that mediates between the diagnostic need and the patient's body. This radiopharmaceutical specifically targets endometriosis tissue through integrin binding, serving as an intermediary carrier that enables accurate diagnosis without direct surgical contact, thereby reducing patient trauma.
2Object-affected harmful factors
If non-invasive imaging techniques (ultrasound, MRI) are used, then patient trauma is reduced, but diagnostic accuracy worsens
Solution Approach 1:
The patent changes the fundamental parameter of tissue targeting by using a radiopharmaceutical with specific molecular affinity for integrins overexpressed on endometriosis tissue. This molecular-level parameter change enables the non-invasive technique to achieve diagnostic accuracy comparable to surgery, overcoming the limitation of conventional imaging that relies only on anatomical visualization.
Solution Approach 2:
The patent employs a composite radiopharmaceutical system combining 99mTc (radioisotope for detection) with maraciclatide (peptide targeting integrin αvβ3). This composite material provides both the targeting capability needed for accuracy and the imaging capability for non-invasive detection, achieving both reduced trauma and high diagnostic accuracy simultaneously.
3Device complexity
If conventional imaging is used, then device complexity is reduced, but ability to detect superficial lesions worsens
Solution Approach 1:
The patent replaces conventional mechanical imaging systems (ultrasound transducers, MRI magnets) with a nuclear medicine approach using gamma camera imaging of radiopharmaceutical distribution. This substitution enables detection of superficial lesions through functional molecular targeting rather than relying on anatomical resolution limits, improving lesion detection while using relatively simple gamma camera equipment.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method provides a more accurate and less invasive means of diagnosing endometriosis, reducing radiation exposure, and enabling the detection of superficial lesions, thereby potentially shortening the time to diagnosis and reducing the need for surgical procedures.
Implementation Method 1
The technetium-99m radiopharmaceutical is suitably prepared from a non-radioactive kit... followed by extra-uterine imaging of the radioactive emissions from said 99mTc-maraciclatide in vivo
Data Source
AI summary
The present invention relates to methods of imaging sites of endometriosis using the radiopharmaceutical agent 99m-maraciclatide. The technetium-99m radiopharmaceutical is suitably prepared from a non-radioactive kit containing the RGD peptide maraciclatide. Also described are methods of diagnosis, therapy selection and therapy monitoring of endometriosis using the agent. The invention also includes the use of the kit and/or gamma camera or gamma detector in the methods of the invention.